The Third Way? Von Eschenbach Promotes Behind-The-Counter Drug Class
Executive Summary
FDA and industry should immediately begin pursuing the development of a regulatory process for a behind-the-counter class of drugs, FDA Commissioner Andrew von Eschenbach told the Consumer Healthcare Product Association's annual executive conference
You may also be interested in...
FDA Plans Behind-The-Counter Meeting, Mulls “Transitional” Status
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders
FDA Plans Behind-The-Counter Meeting, Mulls “Transitional” Status
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders
Risk Management Only Part Of Behind-The-Counter Orders – Von Eschenbach
Enactment of legislation to strengthen FDA's post-marketing authority is not the only hurdle to clear before the agency could begin requiring "behind-the-counter" sales of certain nonprescription drugs, Commissioner Andrew von Eschenbach says